Romania Lung Cancer Therapeutics Market Report 2022 to 2030

Romania Lung Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Romania Lung Cancer Therapeutics Market will reach a value of $164 Mn from $86 Mn in 2022, growing at a CAGR of 8.4% during 2022-2030. The Lung Cancer Therapeutics Market in Romania is dominated by a few domestic pharmaceutical companies such as Adamed Group, Polpharma Group, and Gedeon Richter Polska. The Lung Cancer Therapeutics Market in Romania is segmented into different types of cancer and different therapy type. Some of the major factors affecting the Romania lung cancer therapeutics market are the prevalence of unhealthy lifestyles, demand for targeted therapies and the presence of highly efficient drugs.

ID: IN10ROPH041 CATEGORY: Pharmaceuticals GEOGRAPHY: Romania AUTHOR: Dr. Vishwa Modhia

Buy Now

Romania Lung Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Romania Lung Cancer Therapeutics market will reach a value of $164 Mn from $86 Mn in 2022, growing at a CAGR of 8.4% during 2022-2030.

Romania is an upper-middle-income, developed country located at the crossroads of Central and Southeastern Europe. Lung cancer is the most common cancer in men and the fourth most common in women in Romania, and its incidence and mortality rates are increasing. Recently, strict anti-tobacco regulations were introduced in accordance with the World Health Organization's MPOWER plans. As of January 2012, the 2009 edition of the European Society for Medical Oncology (ESMO) guidelines remained the accepted "official" standard of care in lung cancer. Cancer is the second leading cause of mortality in Romania, after cardiovascular disorders, and the pharmaceuticals used to treat cancer are sponsored through a special National Oncology Program. Squamous cell carcinoma is more common in Romanian patients than in Western Europeans, with less adenocarcinoma.

According to the latest WHO data published in 2020 Lung Cancers Deaths in Romania reached 10,113 or 4.33% of total deaths. The age-adjusted Death Rate is 28.30 per 100,000 of the population ranks Romania 18^th in the world. Romania's government spends 6.3% of its GDP on healthcare.

Romania Lung Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers

Clinical research is quickly expanding, and Romanian institutes have a high recruitment rate in pivotal trials, despite initial delays caused by tardy study approval by authorities. Anti-tobacco initiatives have been implemented in accordance with the WHO's MPOWER strategies. Romania has a broad and competitive industry due to its low labour costs. In 2001, the EU included Romania in its "Golden Growth" scheme. These aspects could boost Romania's Lung Cancer Therapeutics market.

Market Restraints

All new pharmaceuticals approved by the European Medicines Agency in Europe are also approved in Romania. However, since 2008, no new medications (such as gefitinib) or indications (such as first-line tyrosine-kinase inhibitors or maintenance treatment) have been approved for reimbursement. Because of a typically underfunded healthcare system, some unresolved problems and inequities in the management of lung cancer patients persist. Romania's population is decreasing due to low birth rates and youth exodus. These factors may deter new entrants into the Romania Lung Cancer Therapeutics market.

Competitive Landscape

Key Players

Terapia: Terapia is a Romanian pharmaceutical company that specializes in the development, production, and distribution of generic medicines. The company offers a range of lung cancer treatments including chemotherapy drugs and targeted therapies
Biofarm: Biofarm is a Romanian pharmaceutical company that specializes in the production of generic and branded medicines. The company offers a range of lung cancer treatments including chemotherapy drugs and targeted therapies
Zentiva: Zentiva is a Romanian pharmaceutical company that specializes in the production of generic medicines. The company offers a range of lung cancer treatments including chemotherapy drugs and targeted therapies
Polisano: Polisano is a Romanian pharmaceutical company that specializes in the production of generic and branded medicines. The company offers a range of lung cancer treatments including chemotherapy drugs and targeted therapies

Healthcare Policies and Reimbursement Scenarios

The National Agency for Medicines and Medical Devices (ANMDM) in Romania is the regulatory authority in charge of the approval and regulation of therapeutic items, including lung cancer therapies. Cancer treatment is free because the National Program of Oncology funds all cytotoxic drugs and targeted therapy. A centralised panel does, however, individually authorise reimbursement for many pricey medications such as pemetrexed, erlotinib, and bevacizumab.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Lung Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Small Cell Lung Cancer
Non-small Cell Lung Cancer
Lung Carcinoid Tumor

By Therapy (Revenue, USD Billion):

Radiation Therapy
Targeted Therapy
Immunotherapy
Chemotherapy
Others

By Type of Molecule (Revenue, USD Billion):

Small Molecules
Biologics

By Drug Class (Revenue, USD Billion):

Alkylating Agents
Antimetabolites
Multikinase Inhibitors
Mitotic Inhibitors
EGFR Inhibitors
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.